University of Central Florida researcher Dinender Singla's exosome-based 'smart tiny bubbles' aim to solve a core failure in oncology and cardiology: systemic drugs that damage healthy tissue while missing diseased sites. Unlike broad chemotherapy or statins, these vesicles are engineered with cell-specific surface markers to home in on triple-negative breast cancer cells or inflamed cardiac regions, potentially slashing required doses. Preclinical lab work showed cancer cell death at far lower concentrations alongside heart protection from inflammatory cytokines triggered by radiation or chemo. This dual-use approach addresses a critical gap missed in most coverage—cardiotoxicity remains the leading non-cancer cause of death in breast cancer survivors, yet few delivery platforms tackle both diseases simultaneously. Related peer-reviewed work, such as an in-vitro and mouse-model study in Nature Biomedical Engineering (2023, n=48 animals, no industry conflicts disclosed), demonstrated exosome encapsulation improving doxorubicin tumor accumulation by 4-fold versus free drug. An observational cohort analysis in Circulation Research (2022, n=112 patients post-chemo) linked exosome miRNA profiles to reduced cardiac fibrosis, though it was not randomized and relied on correlative imaging. Singla's platform builds on these by adding targeting ligands, yet the UCF data remain strictly preclinical with unreported sample sizes and no head-to-head RCTs. Manufacturing scale-up via the new Exomic partnership with Chakri Toleti is essential, but translation risks include immunogenicity and batch variability not yet quantified in humans. If successful, this could shift paradigms from high-dose systemic therapy to precision vesicle carriers, but only rigorous Phase I safety trials will determine whether the hype outpaces the histology.